Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32


Antibody-targeted chromatin enables effective intracellular delivery and functionality of CRISPR/Cas9 expression plasmids.

Killian T, Buntz A, Herlet T, Seul H, Mundigl O, Längst G, Brinkmann U.

Nucleic Acids Res. 2019 Jun 4;47(10):e55. doi: 10.1093/nar/gkz137.


Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.

Buntz A, Killian T, Schmid D, Seul H, Brinkmann U, Ravn J, Lindholm M, Knoetgen H, Haucke V, Mundigl O.

Nucleic Acids Res. 2019 Jan 25;47(2):953-969. doi: 10.1093/nar/gky1158.


Diphthamide affects selenoprotein expression: Diphthamide deficiency reduces selenocysteine incorporation, decreases selenite sensitivity and pre-disposes to oxidative stress.

Mayer K, Mundigl O, Kettenberger H, Birzele F, Stahl S, Pastan I, Brinkmann U.

Redox Biol. 2019 Jan;20:146-156. doi: 10.1016/j.redox.2018.09.015. Epub 2018 Sep 26.


Transcytosis of payloads that are non-covalently complexed to bispecific antibodies across the hCMEC/D3 blood-brain barrier model.

Schmid D, Buntz A, Hanh Phan TN, Mayer K, Hoffmann E, Thorey I, Niewöhner J, Vasters K, Sircar R, Mundigl O, Kontermann RE, Brinkmann U.

Biol Chem. 2018 Jun 27;399(7):711-721. doi: 10.1515/hsz-2017-0311.


Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.

Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):5997-6002. doi: 10.1073/pnas.1408766112. Epub 2015 Apr 27.


Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.

Schmittnaegel M, Levitsky V, Hoffmann E, Georges G, Mundigl O, Klein C, Knoetgen H.

Cancer Immunol Res. 2015 Jul;3(7):764-76. doi: 10.1158/2326-6066.CIR-15-0037. Epub 2015 Feb 17.


Hapten-directed spontaneous disulfide shuffling: a universal technology for site-directed covalent coupling of payloads to antibodies.

Dengl S, Hoffmann E, Grote M, Wagner C, Mundigl O, Georges G, Thorey I, Stubenrauch KG, Bujotzek A, Josel HP, Dziadek S, Benz J, Brinkmann U.

FASEB J. 2015 May;29(5):1763-79. doi: 10.1096/fj.14-263665. Epub 2015 Feb 10.


Quantification of cell surface proteins with bispecific antibodies.

Panke C, Weininger D, Haas A, Schelter F, Schlothauer T, Bader S, Sircar R, Josel HP, Baer U, Burtscher H, Mundigl O, Grote M, Brinkmann U, Sustmann C.

Protein Eng Des Sel. 2013 Oct;26(10):645-54. doi: 10.1093/protein/gzt035. Epub 2013 Aug 19.


Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S, Duong MN, Reslan L, Gerdes CA, Friess T, Baer U, Burtscher H, Weidner M, Dumontet C, Umana P, Niederfellner G, Bacac M, Klein C.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.


Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.

Schneider B, Grote M, John M, Haas A, Bramlage B, Ickenstein LM, Jahn-Hofmann K, Bauss F, Cheng W, Croasdale R, Daub K, Dill S, Hoffmann E, Lau W, Burtscher H, Ludtke JL, Metz S, Mundigl O, Neal ZC, Scheuer W, Stracke J, Herweijer H, Brinkmann U.

Mol Ther Nucleic Acids. 2012 Sep 18;1:e46. doi: 10.1038/mtna.2012.39.


Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.

Doleschel D, Mundigl O, Wessner A, Gremse F, Bachmann J, Rodriguez A, Klingmüller U, Jarsch M, Kiessling F, Lederle W.

J Nucl Med. 2012 Feb;53(2):304-11. doi: 10.2967/jnumed.111.091124. Epub 2012 Jan 6.


Allosteric antibody inhibition of human hepsin protease.

Koschubs T, Dengl S, Dürr H, Kaluza K, Georges G, Hartl C, Jennewein S, Lanzendörfer M, Auer J, Stern A, Huang KS, Packman K, Gubler U, Kostrewa D, Ries S, Hansen S, Kohnert U, Cramer P, Mundigl O.

Biochem J. 2012 Mar 15;442(3):483-94. doi: 10.1042/BJ20111317.


Bispecific digoxigenin-binding antibodies for targeted payload delivery.

Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, Georges G, Josel HP, Dziadek S, Hopfner KP, Lammens A, Scheuer W, Hoffmann E, Mundigl O, Brinkmann U.

Proc Natl Acad Sci U S A. 2011 May 17;108(20):8194-9. doi: 10.1073/pnas.1018565108. Epub 2011 May 2.


Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, Mössner E, Umana P, Hopfner KP, Klein C.

Blood. 2011 Jul 14;118(2):358-67. doi: 10.1182/blood-2010-09-305847. Epub 2011 Mar 28.


Expression and targeting of the tight junction protein CLDN1 in CLDN1-negative human breast tumor cells.

Hoevel T, Macek R, Mundigl O, Swisshelm K, Kubbies M.

J Cell Physiol. 2002 Apr;191(1):60-8.


Amphiphysin I antisense oligonucleotides inhibit neurite outgrowth in cultured hippocampal neurons.

Mundigl O, Ochoa GC, David C, Slepnev VI, Kabanov A, De Camilli P.

J Neurosci. 1998 Jan 1;18(1):93-103.


The synaptic vesicle cycle: a single vesicle budding step involving clathrin and dynamin.

Takei K, Mundigl O, Daniell L, De Camilli P.

J Cell Biol. 1996 Jun;133(6):1237-50.


Polarized expression of GABA transporters in Madin-Darby canine kidney cells and cultured hippocampal neurons.

Ahn J, Mundigl O, Muth TR, Rudnick G, Caplan MJ.

J Biol Chem. 1996 Mar 22;271(12):6917-24.


A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals.

David C, McPherson PS, Mundigl O, de Camilli P.

Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):331-5.


v- and t-SNAREs in neuronal exocytosis: a need for additional components to define sites of release.

Galli T, Garcia EP, Mundigl O, Chilcote TJ, De Camilli P.

Neuropharmacology. 1995 Nov;34(11):1351-60. Review.


Cellubrevin and synaptobrevins: similar subcellular localization and biochemical properties in PC12 cells.

Chilcote TJ, Galli T, Mundigl O, Edelmann L, McPherson PS, Takei K, De Camilli P.

J Cell Biol. 1995 Apr;129(1):219-31.


A radioimmunoassay to monitor synaptic activity in hippocampal neurons in vitro.

Mundigl O, Verderio C, Krazewski K, De Camilli P, Matteoli M.

Eur J Cell Biol. 1995 Mar;66(3):246-56.


Mechanisms of synaptogenesis in hippocampal neurons in primary culture.

Matteoli M, Verderio C, Krawzeski K, Mundigl O, Coco S, Fumagalli G, De Camilli P.

J Physiol Paris. 1995;89(1):51-5. Review.


Formation of synaptic vesicles.

Mundigl O, De Camilli P.

Curr Opin Cell Biol. 1994 Aug;6(4):561-7. Review.


A signal located within amino acids 1-27 of GAD65 is required for its targeting to the Golgi complex region.

Solimena M, Dirkx R Jr, Radzynski M, Mundigl O, De Camilli P.

J Cell Biol. 1994 Jul;126(2):331-41.


Tetanus toxin-mediated cleavage of cellubrevin impairs exocytosis of transferrin receptor-containing vesicles in CHO cells.

Galli T, Chilcote T, Mundigl O, Binz T, Niemann H, De Camilli P.

J Cell Biol. 1994 Jun;125(5):1015-24.


Morphologic and biochemical analysis of the intracellular trafficking of the Alzheimer beta/A4 amyloid precursor protein.

Caporaso GL, Takei K, Gandy SE, Matteoli M, Mundigl O, Greengard P, De Camilli P.

J Neurosci. 1994 May;14(5 Pt 2):3122-38.


Synaptic vesicle proteins and early endosomes in cultured hippocampal neurons: differential effects of Brefeldin A in axon and dendrites.

Mundigl O, Matteoli M, Daniell L, Thomas-Reetz A, Metcalf A, Jahn R, De Camilli P.

J Cell Biol. 1993 Sep;122(6):1207-21.


Traffic of synaptic vesicle proteins in polarized and nonpolarized cells.

Cameron P, Mundigl O, De Camilli P.

J Cell Sci Suppl. 1993;17:93-100. Review.


Supplemental Content

Loading ...
Support Center